Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOLAR MAKES UP LOST GROUND WHILE INDEX REMAINS FLAT PRIOR TO LABOR DAY

Executive Summary

Bolar (up 3-3/8 to 16-1/2) quickly rebounded from its nearly five-point setback two weeks ago by turning in the best gain on the "F-D-C" Index during the week ended Aug. 30. The stock's 26% price increase in five days came on the heels of an announcement that the company would comply with FDA wishes by shipping previously reformulated generic products in their original NDA-approved formulations ("The Pink Sheet" Aug. 26, p. 3). Alza (up 2-1/4 to 24-1/4) was the only other major gainer among the Pharmaceuticals during a sluggish trading week for Indes issues and for Wall Street in general. Chart omitted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel